Kedrion Biopharma strengthens its position on the US market
Granted exclusive rights to commercialize a lifesaving drug in the US, the Italian company Kedrion Biopharma strengthens its position on the US market.
The product will enable the company, based in Castelvecchio Pascoli (Lucca), Italy’s leader and the 5th most important manufacturer of plasma-derived products in the world, to strengthen its immunoglobulin
portfolio in the US.
The result is a seven year agreement signed with the US company
Biotest Pharmaceuticals Corporation, a subsidiary of Biotest AG, Dreieich, Germany. Kedrion Biopharma began its activities in the United States eleven years ago, opening three plasma-collection centers which
now have become twelve. Over the years, the company’s US operations have also been boosted by a number of major investments.
The present agreement will enable Kedrion Biopharma to further increase the turnover generated by its operations in the US, which are currently the Lucca-based company’s main market. In addition to which, this deal will have implications on Kedrion Biopharma’s activities in Italy as well, as it
has already been decided that, in the future, a phase of the manufacturing process (filling) will be carried out at the company’s facility in Bolognana, Lucca.